Sector News

EMA chief Rasi kicked out as tribunal annuls appointment

November 14, 2014
Life sciences
The European Medicines Agency’s executive director Guido Rasi has been forced to step down after his appointment, made three years, was annulled by a EU panel.
 
The European Union Civil Service Tribunal has ruled on an appeal by an individual against the selection procedure in 2011 for the appointment of executive director of the EMA. The unnamed person brought the case in January 2012 following the decision by the European Commission not to include him on the shortlist of candidates.
 
The court has, “on purely formal grounds”, annulled the Commission’s decision of adopting a shortlist and as a consequence, the choice of Dr Rasi (pictured) has also been annulled.
 
Sir Kent Woods, chair of the EMA management board, noted “with regret” the tribunal’s judgement, saying “it is important to remember that the ruling is about a procedural formality. It is not a reflection on Guido Rasi’s competence or ability to run the agency, something which he has done successfully since November 2011.”
 
The European Commission and EMA are both taking legal advice. “Pending further decisions”, Andreas Pott, the agency’s deputy executive director, will take over.
 
By Kevin Grogan
 
Source: Pharma Times
 

comments closed

Related News

May 21, 2022

As monkeypox cases emerge in US and Europe, Bavarian Nordic inks vaccine order

Life sciences

A monkeypox outbreak is emerging in the U.S. and Europe, and at least one country is amping up countermeasure preparedness. Bavarian Nordic has secured a contract with an unnamed European country to supply its smallpox vaccine, called Imvanex in Europe, in response to the emergence of monkeypox cases, the Danish company said Thursday.

May 21, 2022

Moderna chairman Afeyan defends hiring practices after CFO debacle: report

Life sciences

Moderna’s recent chief financial officer debacle—in which Jorge Gomez departed on his second day on the job—raised questions about the company’s hiring process given its rush to global biopharma prominence. The most obvious one: How was it possible for Gomez to be hired when he was under investigation by his previous employer, Dentsply Sirona of Charlotte, N.C.

May 21, 2022

Merck to pay up to $1.4B in cancer deal with Kelun, but details are scarce

Life sciences

Merck & Co. is plucking a cancer project from the branch of Chinese-based Kelun Pharmaceutical for up to $1.4 billion, but details from the New Jersey-based Big Pharma have been hard to come by. The deal, first disclosed Monday on the Shenzhen stock exchange, has Merck handing over $47 million in upfront cash in exchange for ex-China rights to a “macromolecular tumor project.”